Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.
It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity therapies, having aired an ad in 2024 that urged people not to use them for ...
22m
Lilly isn't alone in this, Danish drugmaker Novo Nordisk - which markets blockbuster weight loss drug Ozempic - too had ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...
The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...
The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...
Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback